New Web-Based Tools Make Systems Pharmacology More Accessible Using Data from the NCI-60
Gene Chip is one of five microarray platforms used to determine gene expression.
High-throughput biological techniques, like microarrays and drug screens, generate an enormous amount of data that may be critically important for cancer researchers and clinicians. Being able to manipulate the data to extract those pieces of interest, however, can require computational or bioinformatics skills beyond those of the average scientist.
One rich source of information is the NCI-60 panel of tumor cell lines. Originally developed to screen anti-cancer compounds by the NCI Developmental Therapeutics Program, these 60 cell lines have also been analyzed for their gene and microRNA expression levels, DNA mutation status, and DNA copy number variations. Researchers from CCR and the Division of Cancer Treatment and Diagnosis, led by Yves Pommier, M.D., Ph.D., of CCR’s Laboratory of Molecular Pharmacology, wanted to make this data more readily available so they generated a series of online tools, which are freely accessible through their CellMiner web-application.
The tools, described in a recent Cancer Research paper, allow users to access expression levels for 26,065 genes and 360 microRNAs as well as the activity of 20,503 compounds, including 98 that are already approved by the Food and Drug Administration. An additional tool that performs pattern comparisons can be used to identify connections between these three parameters or with a user-supplied pattern of interest. The tools perform the complex computational tasks required to normalize the data captured from five distinct microarray platforms and varying numbers of drug experiments and present it in a format that is easier for users to analyze.
To demonstrate the usefulness of their tools, the researchers tested a colon-specific pattern. Of the genes with a high expression level that were returned, two are known to be over-expressed in colon cancer, and a third, which had the highest expression, is a little-studied gene that may make an excellent colon cancer biomarker. Several drugs were also highly active in colon cancer cell lines. Three of these are currently being tested in clinical trials, while the fourth drug with the strongest colon-specific activity pattern, could be considered for testing. Looking at the activity pattern across all 60 cell lines for one of the drugs under clinical investigation, the researchers also noted strong activity in melanoma cell lines suggesting the drug could be a therapy for that cancer type as well.
The researchers plan to add more tools in the future including two that provide access to DNA copy number variations and whole genome sequences across the NCI-60. Together, these freely available tools can help researchers with little bioinformatics training find novel hypothesis-generating associations from data previously buried in complex databases.
Summary Posted: 7/2012
Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, Doroshow J, and Pommier Y. Web-based genomic and pharmacologic tools for gene and microRNA transcript levels, drug activities, and their pattern comparisons across the NCI-60. Cancer Research. July 16, 2012. PubMed Link
Note: All questions should be directed to TellCCR
- Tumor-Protective Mechanism Identified from Premature Aging Disease
- Inhibiting NANOG Enhances Efficacy of BH3 Mimetics
- Investigating Genetic Alterations in Bladder Cancer
- Histone Variant Regulates DNA Repair via Chromatin Condensation
- DNA Damage Repair Factors have a Tumor Promoting Role in MLL-fusion Leukemia
- COX-2 – A Novel Target for Reducing Tumor Angiogenesis and Metastasis
- Identifying Monoclonal Antibodies that Potently Inhibit MERS-CoV
- HIV Integration at Certain Sites in Host DNA is Linked to the Expansion and Persistence of Infected Cells
- Mitochondrial Enzyme Plays Critical Role in Chemotherapy-Induced Heart Damage
- Novel Structure of Ty3 Reverse Transcriptase
- Investigating the Role of NOS2 in Breast Cancer
- Large Population-Based Study Reveals Disparities in Myeloma Precursor Disease
- Small Molecule Disrupts Abnormal Gene Fusion Associated with Leukemia
- Changes in miRNAs Signal High-Risk HPV Infections